Britain and America have concluded a key trade agreement that will maintain zero levies on UK medicine exports entering the American market.
Agreement Details of the Deal
In exchange for the tariff guarantee, the UK has agreed to increase funding on medicines through the National Health Service (NHS). This move secures that tariffs on these key goods will remain at zero for a duration of the next three years.
This development comes after previous threats to significantly raise import taxes on patented drug imports, with increases floated as high as 100%.
"This agreement between the UK reinforces the international landscape for new treatments and introduces much-needed equity to U.S.–U.K. medicine commerce," a statement noted.
Trade Importance
Drugs are one of the Britain's largest export categories to the America, which is by far the largest market for leading UK drugmakers.
Statistics reveal that in the year leading up to the third quarter, the UK shipped medicines valued at billions to the US. This figure represented nearly one-fifth of British export trade in that timeframe.
"This deal protects jobs, boosts capital expenditure and facilitates the UK to establish itself as a worldwide center for biotech and pharma," a government official stated.
Specific British Pledges
The pact involves several key changes from the British government:
- Price Threshold Increase: The UK will raise the cost ceiling at which it judges new treatments to be too expensive by a quarter.
- Higher Drug Budget: There is a aim to double overall NHS spending on medicines from 0.3% of the national economy to 0.6 percent over the coming ten years.
- Refund Ceiling: The sum drug companies must refund to the NHS to prevent overspending will be capped at fifteen percent. Previously, rebates exceeded 20%.
Recent Tensions
The deal comes amid a protracted tension between the pharmaceutical industry and the UK government over medicine costs and regulatory access.
The disagreement were exacerbated by claims that American consumers were charged several times more for the equivalent treatments than people in the Britain and the EU.
Over the last 18 months, several significant pharmaceutical investments in the UK have been halted or cancelled, while major investments have been directed toward US facilities.
One official acknowledged that the NHS must increase expenditure on medicines, noting that its spending on drugs had declined as a proportion of its resources over the last ten years.
